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Abstract 
 
Papillomavirus oncoprotein E6 is a critical factor in the modulation of cervical cancer in 
humans. At the molecular level, formation of the E6-E6AP-p53 ternary complex, which directs 
S¶V GHJUDGDWLRQ LV WKH NH\ LQVWLJDWRU RI cancer transforming properties. Herein, a Cu2+ 
anthracenyl-terpyridine complex is described which specifically induces the aggregation of E6 
in vitro and in cultured cells. For a hijacking mechanism, both E6 and E6AP are required for 
p53 ubiquitination and degradation. The Cu2+ complex interacts with E6 at the E6AP and p53 
binding sites. We show that E6 function is suppressed by aggregation, rendering it incapable 
of hijacking p53 and thus increasing its cellular level. Therapeutic treatments of cervical cancer 
are currently unavailable to infected individuals. We anticipate that this Cu2+ complex might 
open up a new therapeutic avenue for the design and development of new chemical entities for 
the diagnosis and treatment of HPV-induced cancers. 
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Introduction 
High-risk HPV infection is the leading cause of nearly all cases (99.7 %) of cervical cancer [1]. 
It integrates into the host¶V DNA and infects the basal cells of cervix, resulting in the production 
of damaged and disorganized cervical cells. The concomitant loss of function leads to the 
development of cancer. Over 170 types of HPV are known, of which more than 40 are sexually 
transmitted. Around 13 high-risk types of HPV are known to cause cervical cancers [2], with 
types 16 and 18 being the most prevalent, causing over 70 % of cervical cancers [3]. More than 
80 % of women are infected with genital HPV at some point in their lives which often leads to 
cervical cancer [4]. Although HPV infection is widespread, its symptoms are seldom 
noticeable. 
 
The genome of HPV 16 and 18 is ~8 kb, which is made-up of double-stranded DNA. Of the 
eight different types of proteins encoded by the HPV genome, only E6 and E7 proteins exhibit 
cancer inducing properties. These proteins functions include immortalization of primary cell 
lines, activation of transmembrane signalling and alteration of the cell cycle etc. Thus, E6 and 
E7 are known to exhibit pleiotropic functions. Thus, E6 and E7 are considered necessary for 
malignant conversion. The interactions of E6 and E7 with p53 and pRB, respectively, have 
been suggested to be implicated in the mechanism of inducing tumor formation [5-9]. The E6 
protein promotes the formation of a trimeric protein complex composed of E6, p53 and the 
cellular ubiquitination enzyme E6AP [10, 11]. This stimulates degradation of p53 and thereby 
promotes unregulated cell proliferation, finally leading to increased tumor cell growth [9]. This 
explains why very low levels of p53 are observed in cervical carcinoma cell lines [12]. 
Moreover, E6 can perform its oncogenic activities without the cross-talk of p53 [13, 14]. 
Discovery of E6 targets is continuous, several have been identified recently. Example include, 
IRF-3, E6TP1, p300/CBP, ADA3, Gps2 and hMcm7, (transcription and DNA replication 
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regulatory proteins) and cMyc, FADD, Bak and TNF receptor 1 (apoptosis and immune 
evasion regulatory molecules). Besides these, E6 also targets proteins included in cell 
differentiation, cell-cell adhesion, epithelial cell organization, cell polarity and DNA repair [7-
9, 13-15].  
 
Recent studies of the structure of an E6/E6AP/p53 complex suggested that ternary complex 
formation is required for HPV-mediated degradation of p53 [10]. The complex structure also 
showed that E6 forms a distinct pocket for E6AP and a cleft for p53 binding. Recent 
experimental evidence using pro-apoptotic peptides and small molecules highlighted that the 
E6AP binding pocket is druggable [16-18]. Additionally, the p53 binding cleft may represent 
a second potential drug binding site [10]. Therefore, HPV E6 could be an efficient drug target 
in order to combat cervical cancer. 
Small molecules including coordination complexes are known for their antitumor activities. 
Cis-platin is a one such example of a coordination complex. Its mechanism of action involves 
the formation of adducts with DNA, leading to cell death. It is also being developed as a lead 
molecule against amyotrophic lateral sclerosis based on its interaction with superoxide 
dismutase [19, 20]. Complexes with other metal ions including Cu2+ are under intense 
investigation [21, 22]. Cell toxicity is well known for copper itself, however, its complexes 
which exhibit several fold better responses are under consideration. Several studies have shown 
the antiproliferative activity of cupper complex exhibited up to several-hundred fold better 
responses compared to Cu2+ alone [21, 23-25]. 
Several of these organometallic complexes have been shown to exhibit antiproliferative, 
antimicrobial and antifungal activity by adding and incubating them to cultured media. 
However, the molecular mechanism behind their cytotoxicity remains elusive [26, 27]. In a 
structure based drug-design, the physico-chemical nature of the molecules often render them 
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incapable of crossing cell wall/membrane barrier to reach their targets in a complex cellular 
environment, although they are quite effective binding-partners under in vitro conditions [28]. 
Thus, small molecules which penetrate the cell and interact with crucial molecules are 
advantageous [29, 30]. Cell based rational screening identified a Cu2+ complex which caused 
E6 to aggregate, we have subsequently explored the molecular mechanism of action. We 
confirmed that this Cu2+ complex interacts with the E6 oncoprotein, causes its aggregation 
inside the cells which is manifested by the formation of granular structures. Only HPV infected 
cells display such aggregates. Under in vitro conditions, the Cu2+ complex binds E6 with micro-
molar affinity and also with those residues forming the E6AP and p53 binding sites. Subsequent 
self-association forms aggregated structures under in vitro conditions similar to those observed 
inside the HPV-containing HeLa cells. Eventually, this led to stabilization of p53 inside the 
cells.  
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Results  
Cu2+ complex induces aggregation of isolated E6 F47R 4C/4S 
Wild-type oncogenic E6 has a tendency to aggregate under isolated in vitro conditions [31, 32]. 
Therefore, a soluble construct of E6 (His6-MBP-tev-F47R E6 4C/4S) was expressed and 
purified via the bacterial-expression system as described previously [32]. For HPV16 E6, we 
purified the monomeric E6 F47R 4C/4S variant that combines the F47ÆR47 (F47R) mutation 
which disrupts the dimerization facilitated by the N-terminal domain () with four mutations at 
non-conserved cysteines (C80S, C97S, C111S and C140S) preventing disulfide-mediated 
aggregation [32]. In order to test whether the Cu2+ complex (stable, water soluble and 
structurally characterized) can induce the aggregation of E6 F47R 4C/4S in isolation, the 
complex and ligand were co-incubated for 6 h. Samples were taken out at each hour and 
analysed by electron microscopy. The results show that E6 F47R 4C/4S aggregates in the 
presence of the Cu2+ complex under in vitro conditions and well-defined spherical structures 
formed at longer times (Figure 1A). The sample, which was incubated for 6 h, was centrifuged 
at 30,000 rpm and the obtained pellet was washed with buffer and loaded onto SDS-PAGE. 
The Coomassie brilliant blue-stained gel shows an intense band corresponding to monomeric 
E6 F47R 4C/4S and additional bands for higher oligomers (Figure 1B) thus confirming that the 
pelletable material was proteinaceous and sedimented due to the aggregation of E6 F47R 
4C/4S. In addition, Cu2+-perchlorate or 9-anthracene methanol were used as control molecules. 
Both did not induce the formation of such aggregates when analysed by EM or SDS-PAGE 
(Figure 1B ).  
 
Fluorescence correlation spectroscopy (FCS) is a technique well-suited to study the diffusion 
of proteins and obtain their hydrodynamic radii in solution. E6 F47R 4C/4S has 10 cysteines, 
of which 8 are involved in forming coordination bonds with zinc, with the remaining two 
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cysteines free. Therefore, E6 F47R 4C/4S was labelled with the dye Alexa-488 using 
maleimide chemistry. The Cu2+ complex-induced aggregation of E6 F47R 4C/4S was 
monitored for 0 ± 6 h doped with 1 % (v/v) Alexa-488-labelled E6 F47R 4C/4S. Analysis of 
the autocorrelation curves revealed hydrodynamic radii (RH) of 2.1, 2.5, 82.4, 276.8, 366.4, 
445.2, and 1128.8 nm after 0, 60, 120, 180, 240, 300 and 360 minutes of incubation, 
respectively. During the first hour, oligomeric species form which are approximately five times 
larger than the monomer. After this lag time, the Cu2+ complex induces the formation of E6 
F47R 4C/4S aggregates with increasing size, in good agreement with the EM data. It is notable 
that Cu2+-perchlorate or 9-anthracene methanol have negligible effects on the diffusion of E6 
F47R 4C/4S.  
 
Particles with diameters of 40-2000 nm can be analysed by nanoparticle tracking analysis 
(NTA) [33]. Free form of E6 F47R 4C/4S is not visible under such conditions indicative of the 
homogeneous monodisperse nature of the sample. A co-incubation of E6 F47R 4C/4S and the 
Cu2+ complex for 6 h results in the visualization and quantitation of tracked particles ranging 
from 13 to >800 nm. At 0 h, or after co-incubation with Cu2+-perchlorate or 9-anthracene 
methanol no particles are visible even after 6 h. The NTA data can be corroborated by using 
dynamic light scattering (DLS), a complementary technique. Unlike NTA, DLS is able to 
detect monomeric (<10 nm in radius) as well as aggregated (>10 nm in radius) E6 F47R 4C/4S 
species. Regularization analysis of the free E6 F47R 4C/4S correlogram gives a single peak 
with a mean hydrodynamic radius of 2.3 ± 0.02 nm (corresponding to 100 % abundance) 
expected for a protein of this size and in good agreement with the FCS data. However, Cu2+-
complex-induced aggregation of E6 F47R 4C/4S after 6 h of co-incubation gives a 
polydispersity index of over 0.7 indicative of the formation of aggregates over a broad size 
range. Interestingly, there is no peak corresponding to monomeric protein  in the regularization 
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analysis. It shows three peaks at 7.89 ± 1.22 nm, 357 ± 387 nm and 10000 ± 29700 nm. E6 
F47R 4C/4S in the presence of Cu2+-perchlorate or 9-anthracene methanol gives a single peak 
at 2.3 ± 0.1 nm and 2.4 ± 0.3 nm, respectively, after 6 h of co-incubation. 
 
Interactions of the Cu2+ complex with E6 F47R 4C/4S 
Next, the interactions of the Cu2+ complex with E6 F47R 4C/4S were probed by fluorescence 
spectroscopy. E6 F47R 4C/4S features one tryptophan at position 132 which acts as a highly 
sensitive fluorescence probe for interaction studies. A symptomatic decrease in fluorescence 
intensity was observed upon addition of the Cu2+ complex to protein (Figure 2A), yielding a 
Kd of 1.1 ± 0.06 µM and a stoichiometry of 1:2. Thus, at least two molecules of Cu2+ complex 
bind to E6 F47R 4C/4S. Such binding is expected from organic molecules bearing a 
hydrophobic moiety. The titration with Cu2+-perchlorate did not result in a considerable 
decrease in fluorescence intensity. The binding of E6 F47R 4C/4S to 9-anthracene methanol 
yielded a Kd of 4.95 mM  indicating that both the Cu-metal centre and the organic moiety are 
required for effective binding.  
 
E6 F47R 4C/4S exhibits a characteristic circular dichroism spectrum expected from the 
NMR/X-ray structure [10, 32] of the Dȕ-protein. Titration with the Cu2+ complex showed a 
gradual loss of negative ellipticity at 210 and 220 nm together with a decrease at 195 nm. This 
indicates that E6 F47R 4C/4S undergoes conformational changes of some secondary structure 
elements towards a disordered form. Again, Cu2+-perchlorate or 9-anthracene methanol did not 
induce significant conformational changes.  
 
Cu2+ complex induces intra-cellular aggregation of E6  
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In order to test whether the Cu2+ complex induces the aggregation of E6 inside the cell, HPV-
containing HeLa cells were co-incubated. With the molecules, HPV-infected HeLa cells 
showed spherical aggregated structures within 2 h of incubation. Similar spherical structures 
were observed previously, but, their origin was unclear [23]. These spherical structures give 
rise to blue fluorescence when observed under UV light (334 nm) (Figures 3 A and B). The 
HeLa cells showed an IC50 (concentration at which cells showed 50% viability) value for cell 
viability of 1.03 ± 0.03 µM Cu2+ complex (Figure 3 C). Subsequently, rational screening of 
cells infected with HPV (CaSki, HeLa, SiHa and ME 180) or not (HepG2, MCF7, H1229, 
U2OS, and HEK 293) showed direct correlation of IC50 and involvement of HPV (Figure 3 C). 
Accordingly, CaSki (60-600 copies/cell), HeLa (10-50 copies/cell), SiHa (1-2 copies/cell) and 
ME180 (HPV-68) showed IC50 value of 0.7 ± 0.02 µM, 1.03 ± 0.03 µM, 4.1 ± 0.7 µM, and 
5.20 ± 0.4 µM, respectively. The other cell lines (non HPV-infected) showed similar toxicity 
against Cu2+ complex, with an IC50 range between 5 ± 6 µM (Figure 3 C). Western blotting 
confirmed that the spherical structures are aggregated species of E6. Untreated HeLa cells 
showed similar levels of E6 in the soluble fraction and the cells pellet in lysed cells (Figure 
3D, lanes 1 and 2). In contrast, when the cells were treated with the Cu2+ complex, the majority 
of the E6 protein was observed in the cell pelleted fraction (Figure 3D, lanes 3 and 4). 
 
Although these experiments provided sufficient evidence of Cu2+ complex-induced 
aggregation of E6, it is well known that wild-type E6 aggregates in isolation [31, 32]. 
Therefore, the pellet observed (Figure 3D, lane 4) could be simply induced by cell opening 
(Figure 3D, lane 2). To further confirm E6 aggregation induced by the Cu2+ complex, soluble 
E6 F47R 4C/4S was fused with green fluorescence protein (GFP) and sub-cloned into the 
pFLAG vector for mammalian cell expression. This construct was transiently transfected into 
MCF-7 cells. Note that MCF-7 cells are HPV negative and therefore contain no endogenous 
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E6. The green fluorescence of GFP-E6 F47R 4C/4S inside MCF-7 cells when excited at 488 
nm was broadly distributed throughout the cytoplasm (Figures 3 E and F). Subsequently, these 
cells were co-incubated with the Cu2+ complex which, after 2 h of incubation, showed spherical 
aggregates inside the transfected HCF-7 cells (tMCF-7) (Figures 3 G and H). The transfected 
cells without Cu2+ complex treatment showed maximum expression of GFP-E6 F47R 4C/4S 
in the soluble fraction (Figure 3 I, lane 1 and 2). However, most of the GFP-E6 F47R 4C/4S 
was seen in the pellet when transfected MCF-7 cells were co-incubated with the Cu2+ complex 
(Figure 3 I, lane 3 and 4). The transfected cells showed a three-fold lower IC50 value (1.88 ± 
0.05 ȝ0) compared to the non-transfected MCF-7 cells (5.94 ± 0.5 µM) (Figure 3 C) by the 
MTT cell viability assay. These results confirm that granular structures inside the cells are 
formed due to the aggregation of E6 induced by the Cu2+ complex. Neither, Cu2+-perchlorate 
nor 9-anthracene methanol induce such spherical aggregated structures in HeLa, MCF-7, or 
transfected MCF-7 cells transiently expressing GFP-E6 F47R 4C/4S .  
 
p53 hijacking by E6 can be relieved by the Cu2+ complex 
p53 is a transcription factor that plays a key role in regulating cell cycle progression, DNA 
repair and apoptosis [34]. However, p53 function is masked by E6 in HPV-infected cells (e.g. 
cervical cancer cells [35]) where p53 degradation is a hallmark activity of the HPV E6 protein 
[6-11, 13]. Therefore, we hypothesize that, if we could disrupt E6/E6AP/p53 complex 
formation e.g. by aggregating E6 in the presence of the Cu2+ complex, p53 should not degrade 
and its expression will be stabilized. Western blot analyses show low expression of p53 in 
untreated HeLa cells as expected due to the hijacking nature of E6 (Figure 4A, lane 1). In doing 
so, E6 interacts with the LxxLL motif of E6AP, yielding the E6/E6AP heterodimer [10, 11]. 
This heterodimer recruits and degrades p53 via the ubiquitin-mediated degradation pathways 
[6-13]. However, in Cu2+ complex treated cells, p53 expression is upregulated several fold 
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(Figure 4A, lane 2) suggesting that E6 function is suppressed, most probably by its aggregation. 
Also, neither E6 nor E6AP are independently capable of recruiting p53 for degradation [36, 
37]. Other HPV E6 containing cell line, i.e. CaSki, showed similar p53 stabilization when 
treated with the Cu2+ complex (Figure 4A). Additionally, treated cervical cancer cells showed 
nuclear fragmentation after 48 h of incubation (Figure 4B-G). FACS analysis showed a 55 % 
and 56 % increase in apoptotic peak in HeLa and CaSki cells, respectively, a clear indication 
of apoptotic cell death induced by the Cu2+ complex. In control MCF-7 cells lacking E6, no 
change in p53 expression or nuclear fragmentation after Cu2+ complex treatment was observed 
(Figure 4A, F and G). Taken together, these results suggest that the Cu2+ complex induces the 
apoptotic cell death via the p53 mediated pathway. 
 
Next, we evaluated the residue-based interactions of the Cu2+ complex with E6 F47R 4C/4S, 
which might be involved in disrupting the E6/E6AP/p53 ternary complex and/or inducing 
aggregation, by NMR spectroscopy [38-42]. The recent E6 F47R 4C/4S/E6AP/p53-core 
ternary complex structure suggested that the E6-p53 interface can be sub-divided into three 
regions [10, 32]. E6 F47R 4C/4S residues at sub-interface I include: Met1-Arg8, Arg10, Lys11, 
Gln14 and Glu18; at sub-interface II Ile23, His24, Tyr43, Asp44, Phe47, and Asp49, and at 
sub-interface III; Leu100 and Pro112. The E18A/R point mutation of E6 impaired 
E6/E6AP/p53 ternary complex assembly, while D44R and D49A substitutions hindered p53 
degradation in addition to complex assembly [10]. After addition of the Cu2+ complex (Figure 
4H, I and 5), the NMR intensity of these interface residues revealed almost complete signal 
loss for Glu18, Asp44 and Asp49 and significant intensity decreases for Glu7, Arg8, 
Arg10,Ile23, and R47 (marked red in Figure 4 H and I), while residues Met1-Gln6, Lys11, 
Gln14, His24, Tyr43 and Leu100 remain almost unaffected. NMR intensities decreased for 
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those residues, which are in close proximity to the paramagnetic Cu2+ moiety, because of 
paramagnetic relaxation enhancement [19, 29].  
 
E6 possesses a conserved LxxLL binding pocket formed by residues from the N- and C-
terminal domains (denoted as E6N and E6C in Figure 4I) also harbouring the Zn-binding site 
and the linking helix. Val31, Tyr32, Leu50, Cys51, Val53, Val62, Leu67, Tyr70, Ile73 and 
Leu100 of E6 contribute to the LxxLL binding pocket [10, 11]. NMR titration shows that the 
intensities of Val31, Leu50, Cys51, Val53 and Ile73 significantly reduced upon addition of the 
Cu2+ complex (marked in magenta in Figure 4 H and I). Thus, various key residues in the N-
terminal domain of E6 F47R 4C/4S indicate that the Cu2+ complex can compete with p53 and 
E6AP binding. In addition, the NMR titration analysis of the whole E6 F47R 4C/4S sequence 
showed that the intensity of many other residues from both the N- and C-terminal domain 
significantly decreased (Figure 5). We anticipate that the local unfolding [43] of E6 F47R 
4C/4S upon Cu2+ complex binding detected by CD spectroscopy might correspond to these 
residues, which are then responsible for inducing E6 F47R 4C/4S aggregation.  
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Discussion 
Gardasil and Cervarix are the marketed HPV vaccines offering preventive care to uninfected 
humans [44, 45]. However, at present, therapeutic treatments are not available to infected 
individuals. Additionally, these vaccines are expensive and the overall five year treatment rate 
is ~90 % for cervical cancer, reducing sharply to 15 % if the cancer has spread to other organs 
(according to the American Cancer Society). We demonstrated that a complex of Cu2+ and 
anthracenyl-terpyridine showed sub-micro-molar inhibition of various cervical cancer cell 
lines. Their IC50 values showed a clear dependency on the number of HPV copies present in 
the cancer cell lines and exhibited granulated structures inside cells. We proposed that the Cu2+ 
complex induces aggregation of HPV-E6 inside cells, eventually causing apoptosis of HVP-
infected cells [23]. As p53 expression levels are quite low in HPV-containing tumor cells, due 
to E6-directed degradation, many therapeutic strategies have been focused on blocking E6 
function, thereby stabilizing p53. An increase in the cellular p53 level and concomitant 
suppression of tumor growth has been achieved in both tissue culture and animal models using 
RNAi or antisense oligo-deoxy-nucleotides [46, 47]. Recently reported crystal structures of the 
ternary complex [10] suggested that another approach is to disrupt the interactions of the E6-
E6AP or E6-p53 heterodimer, inducing cell cycle arrest or apoptosis by increasing p53 levels 
in the infected cells. Several inhibitors such as Pitx2a protein inhibitor [48], D-helical peptides 
[49, 50] and intrabodies [51] have been developed, however, all of these show modest activity. 
An alternate way is to develop small molecules which exhibit the unique phenomenon of 
nullifying the E6 hijacking function and thus stabilizing the cellular p53 level. The Cu2+ 
complex described in the present study exhibits these features by aggregating E6 in vitro and 
stabilizing cellular levels of p53. 
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We tested various other small molecules (such as acid fuchsin, acridine orange, fast green FCF, 
benzimidazole, thioflavin T., vanillin etc) to determine whether or not they can induce E6 F47R 
4C/4S aggregation under in vitro conditions. None of these generated observable E6 F47R 
4C/4S aggregates. Additionally, previous studies about inhibitors developed to disrupt the E6 
ternary complex, never reported aggregation of E6 under any of the experimental conditions 
tested. These studies include a high throughput screen of flavonoids disrupting HPV-16 E6 
function [16], the screening of over 88,000 diverse small molecules as HPV E6 inhibitors [17], 
the small inhibitory peptides [18], chimeric proteins [52], the Pitx2a protein inhibitor [48], D-
helical peptides [49, 50], and intrabodies [51] to name but a few. We also tested whether the 
Cu2+ complex induces aggregation of proteins other than E6 F47R 4C/4S. Although we chose 
a diverse set of proteins including Kti11, a protein which coordinate Zn2+ through four cysteine 
residues [42], or a disulfide bonds rich protein (HSA), none showed formation of well-defined 
spherical aggregates . Therefore we anticipate that inducing the E6 F47R 4C/4S aggregation 
phenomenon by the Cu2+ complex is rather specific.  
 
The aggregates formed by co-incubation of E6 F47R 4C/4S and the Cu2+ complex are well-
defined, round in shape and amorphous in nature. FCS, electron microscopy and dynamic light 
scattering analyses suggest a gradual increase in the size of the aggregates with time up to 1 
ȝPLQGLDPHWHU. The proteinaceous nature of the aggregate was confirmed by SDS-PAGE. An 
NMR titration with the Cu2+ complex revealed the E6 F47R 4C/4S residues sensing binding 
(Figure 5). In vitro dimerization of E6 occurs via the N-terminal domain [32] and the majority 
of residues at the dimer interface (Ile23, Arg39, Tyr43, Asp44, Ala46, and Phe47) are also 
involved in Cu2+ binding (Figure 5A). Note that Phe47 was mutated to Arg in E6 F47R 4C/4S 
to increase the solubility and that mutations of the dimer interface disrupt E6 self-association 
and inactivate E6-mediated p53 degradation [32]. We suggest that the Cu2+
15 
 
the solubility promotion of Arg47 leading to E6 aggregates. We cannot distinguish from the 
data presented here whether disruption of the dimerization or the loss of soluble E6 protein, 
increases p53 levels in vivo upon incubation with the Cu2+ complex. Also, we are unable to 
rule out the possibility that the Cu2+ complex may interact with other cellular proteins.  
 
E6 F47R 4C/4S binds two Cu2+ complexes with micromolar affinity (Kd = 1 µM). Several 
residues affected by this binding are also involved in E6AP and p53 binding (Figure 4H and 
I). Additionally, Cu-perchlorate or 9-anthracene methanol could not establish such residues 
specific interactions. Therefore, we propose that the Cu2+ complex can compete with p53 
hijacking given that the in vitro Kd between E6 F47R 4C/4S and the p53 core is within the same 
range (22 µM according to [10]). Additionally, the Cu2+ complex interacts with four residues 
of E6 F47R 4C/4S (V32, L50, V53, I73), which facilitate E6AP binding (Figures 4 H and I). 
Again we propose that a competition with E6AP is feasible because the E6 F47R 4C/4S/E6AP 
interaction is in the low micromolar range [18].  
 
In summary, we have shown the aggregation of HPV oncoprotein E6 in vitro and inside cells, 
and that this phenomenon is exclusively induced by the Cu2+ complex, leading to increased 
p53 levels thereby shortening life-time of HPV-infected cells by inducing apoptosis. We 
anticipate that the Cu2+ complex described here might lead to the development of drugs which 
specifically target E6 in cancer cells and combat HPV-mediated infections.  
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Experimental section 
 
Protein expression and purification 
The plasmid corresponding to the DNA sequences of HVP 16 E6 F47R E6 4C/4S was cloned 
in the NcoI and KpnI sites of the pETM-41 vector containing an N-terminal His6-MBP tag 
followed by a TEV cleavage site. This plasmid was provided by Dr. Gilles Travé, IGBMC, 
France. F47R E6 4C/4S was purified following the previously reported method [32]. In brief, 
pETM-41 carrying the gene of F47R E6 4C/4S was transformed into the E. coli BL21(DE3) 
cells containing kanamycin as the selection antibiotic. These cells were grown in Luria-Bertani 
media at 37 °C followed by induction with IPTG and further growth for 17 h at 15 °C. The 
MBP-E6 F47R 4C/4S was purified from the soluble fraction using amylose affinity 
chromatography. The fused protein was cleaved by TEV protease and further purified by S75 
gel filtration chromatography. The purity of the protein was analysed on 12 % SDS-PAGE.  
 
Protein aggregation and electron microscopy 
E6 F47R 4C/4S and Cu2+ complex were mixed in a 1:2 ratio ȝ0and incubated at room 
temperature in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT. 
Samples were taken out at 0, 30, 60, 120, 180, 240, 300 and 360 minutes. EM grids were 
immediately prepared by pipetting the mixture onto a Formvar carbon-coated copper grid. The 
grids were washed and VWDLQHGZLWKȝORIZYXUDQ\ODFHWDWH7KHJULGVZHUHH[DPLQHG
using a Zeiss 900 transmission electron microscope operated at an acceleration voltage of 80 
kV. The Cu2+ complex was dissolved in dimethyl sulfoxide (DMSO) and further diluted for 
experiments. The final concentration of DMSO was < 1 % in any experiment. 
The small molecule screening was performed in 20 mM sodium phosphate buffer (pH 6.8), 200 
mM NaCl and 2 mM DTT. In these experiments E6 F47R 4C/4S and small molecule were 
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mixed in a 1:2 ratio of protein:small molecules (20:40 µM). The protein screening was carried 
out in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT. Here, the 
protein solution was mixed with the Cu2+ complex in a 1:2 mol:mol ratio (protein:Cu2+ 
complex). The mixture was incubated at room temperature for 6 h and EM grids were prepared 
as described above.  
 
Fluorescence correlation spectroscopy 
Two of the E6 F47R 4C/4S cysteines are available to be labelled using maleimide chemistry. 
These two cysteine residues in E6 F47R 4C/4S allow site-specific derivatisation using a 
sulfhydryl reactive fluorophore (Alexa Fluor 488 C5 Maleimide, Molecular Probes). E6 F47R 
4C/4S DWȝ0 solution (20 mM sodium phosphate buffer (pH 7), 200 mM NaCl) was mixed 
1:10 (mol:mol) with Alexa Fluor 488 and allowed to conjugate for 4 h at room temperature. 
Unreacted dye was then separated from the E6 F47R 4C/4S using a Superdex peptide column 
(10/300 GL, GE Healthcare). For the aggregation assay, 2ȝORIȝ0RIlabelled E6 F47R 
4C/4S ZDVPL[HGZLWKȝ0RIXQODEHOOHGE6 F47R 4C/4S in 20 mM sodium phosphate buffer 
(pH 6.8), 200 mM NaCl and 2 mM DTT. The Cu2+ FRPSOH[DWȝ0ZDVPL[HGZLWKWKLV
doped mixture. The proteins and Cu2+ complex were mixed in such a way to give the final 
concentration identical LQȝOVROXWLRQ FCS correlograms were recorded at 0, 30, 60, 120, 
180, 240, 300 and 360 minutes on a home-built FCS setup equipped with a Carl Zeiss objective 
lens with 1.45 nuclear apertures and a working distance of 0.11 mm. A green laser (power of 
1 mW) was used for recording the data with confocal volume of 1 fL. Averages of 10 successive 
scans were acquired for a single correlogram. The data were analysed using MATLAB scripts.  
Fluorescence spectroscopy 
The fluorescence experiments were carried out in 20 mM sodium phosphate buffer (pH 6.8), 
200 mM NaCl and 2 mM DTT at 5 µM E6 F47R 4C/4S on a Jasco FP6500. The samples were 
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excited at 280 nm. In a titration experiment, 4 µM of Cu2+ complex was added and spectra were 
recorded after each addition. A blank titration was reference, using Cu2+ complex alone in 
buffer, and these spectral traces were subtracted from the main titration data.  
Fluorescence data were analyzed according to the following equation: 
    112D1D1maxmax 2/4 mLPPnLKnLPKnLPQQQ ¹¸
·
©¨
§
¹¸
·
©¨
§
¹¸
·
©¨
§  
                (1) 
with P = (P0 / (V0 +L))V0 and L1 = (L0 / (V0 + L))L and Q ± fluorescence intensity, P ± protein 
concentration, L ± ligand concentration, V ± volume, n ± binding sites and subscript 0 ± 
indicates start point. 
 
CD spectroscopy 
CD titration experiments were carried out in 20 mM sodium phosphate buffer (pH 6.8), 200 
mM NaCl and 2 mM DTT at 15 µM E6 F47R 4C/4S. In a titration experiment 10 µM of the 
Cu2+ complex was added at each time. Final spectra represented are the average of four 
successive scans. A blank titration containing only the Cu2+ complex was subtracted from the 
spectra from the main titration experiment. CD spectra were recorded on a Jasco-J810 
spectropolarimeter with a scan speed of 20 nm/min using 1 mm path length cuvette. 
 
Dynamic Light Scattering (DLS)  
$UDWLRȝ0RIE6 F47R 4C/4S and Cu2+ complex were mixed and incubated at 
room temperature in 20 mM sodium phosphate buffer (pH 6.8), 200 mM NaCl and 2 mM DTT 
for 6 h. Cu2+-perchlorate or 9-anthracene methanol were also incubated under the same 
conditions. After 6 h LQFXEDWLRQ WLPH  ȝ/ VDPSOHV ZHUH LQMHFWHG LQWR D :\DWW
miniDawnTreos® system (equipped with an additional DLS detector). )LOWHUHGȝPDQG
de-gassed buffer was used to obtain 5 minute baselines before and after sample injection. The 
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flow cell was cleaned after each run using 1 mL of 1 M nitric acid followed by 2 ml each of 
H2O and buffer. Data analysis was performed on a three minute sample window using Astra 
6.0.3 software by the methods of regularization [53] and cumulants analysis [54]. Cumulants 
analysis provided the Z-DYHUDJHUDGLXV]DQGVWDQGDUGGHYLDWLRQıRIthe solution [54]. The 
polydispersity index (PDI) was calculated using the following equation:  ܲܦܫ ൌ  ቆߪଶݖଶቇ 
 
Nanoparticle Tracking Analysis (NTA)  
Nanoparticle tracking analysis was performed on the 1:2 ratio of Cu2+ complex:E6 F47R 4C/4S 
which was incubated for 6 h at room temperature. The same conditions were used in the case 
of Cu2+-perchlorate or 9-anthracene methanol. A Nanosight® LM10 (Malvern Instruments) 
equipped with a 642 nm laser was cleaned with 70 % ethanol and left to dry. 300 µl of samples 
were injected in the instrument and three 90 second videos were recorded. The data was 
analyzed and averaged in the software for each sample. The instrument was set at screen gain 
= 1, detection threshold = 10 nm, T =22 °C, viscosity = 0.95 cP and camera brightness = 10-
16 to minimise background noise.  
 
NMR experiments 
For uniform protein 15N isotope labelling M9 minimal media supplemented with 15N NH4Cl 
was used. E6 F47R 4C/4S was purified as described in the previous section. NMR experiments 
were carried out at 50 µM protein concentration in 20 mM sodium phosphate buffer (pH 6.8), 
200 mM NaCl and 2 mM DTT. The Cu2+ complex was added until no further changes in cross-
peak intensities were observed. NMR spectra were recorded with a Bruker 800 MHz Avance 
III spectrometer equipped with a CP-TCI cryoprobe at 25 °C. Spectra were processed using the 
programs NMRPipe and NMR Draw. The spectrum corresponding to the 1:2 ratio of E6 F47R 
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4C/4S to Cu2+ complex was analysed. Previously assigned NMR resonances [32] were used 
for data analysis. Cu2+-perchlorate or 9-anthracene methanol was mixed with E6 F47R 4C/4S 
at 1:2 ratio and spectrum was recorded as described above.  
 
Cell culture  
Cervical carcinoma cells (HeLa) and breast cancer cells (MCF-7) were cultured in DMEM, 
whilst CaSki (cervical carcinoma cells) were cultured in RPMI media supplemented with 10 
% heat inactivated (56 °C for 30 min) fetal bovine serum (FBS) at 37 °C in a humidified 
chamber with 5 % CO2.  
 
Cell viability assay 
Cell viability was determined by a methylthiazole tetrazolium (MTT) assay. HeLa, MCF-7 or 
transfected MCF-7 cells were co-incubated with increasing amounts of the Cu2+ complex (0 ± 
15 µM). After 48 h of incubation, 50 ȝl of MTT (1 mg/ml) was added and further incubated 
for 4 h at &7KHUHDIWHUȝORI'062ZDVDGGHGDQGDEVRUEDQFHZDVUHFRUGHGDW
nm using 630 nm as a reference filter. The cells measured without the Cu2+ complex were 
considered as having 100 % cell viability. The experiments were performed in triplicates and 
repeated three times. In the control experiment cells were treated with 15 µM of Cu2+-
perchlorate or 9-anthracene methanol. For nuclear fragmentation experiments cells were tested 
at IC50 (HeLa and CaSki cells at 1 µM and MCF-7 cells at 6 µM) and incubated for 48 h.  
 
Transfection experiment 
The MCF-7 cells were transfected by Lipofectamine2000 (Invitrogen) following the 
PDQXIDFWXUHU¶Vinstructions. Semi-confluent (80±90%) MCF-7 cells were transfected with 2 ȝg 
of pFLAG-GFP-E6 F47R 4C/4S. As an internal control, 0.5 ȝg of pEGFPC1 plasmid was 
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added to assess the transfection efficiency. The fLQDO'1$DPRXQWZDVDGMXVWHGWRȝJXVLQJ
the pCDNA plasmid as carrier DNA. This DNA mixture was added to Lipofectamine2000 
(diluted Opti-MEM medium). This mixture was incubated at room temperature for 45 min to 
allow Lipofectamine2000-DNA complex formation. The Lipofectamine2000-DNA complex 
was added drop wise to the MCF-7 cells and mixed gently.  
 
Western blot analysis 
For the Western blot analysis, the cells were treated at the IC50 concentration (HeLa and CaSki 
cells at 1 µM and transfected MCF-7 cells at 2 µM) and incubated for 48 h. Cells were washed 
with ice cold phosphate buffered saline and lysed with lysis buffer (50 mM Tris-Cl, pH 7.5, 
with 120 mM NaCl, 10 mM NaF, 10 mM sodium pyrophosphate, 2 mM EDTA, 1 mM Na3VO4, 
1 mM PMSF, 1% NP-40 and protease inhibitor cocktail). Fifty µg of heated proteins (95 °C 
for 10 min) in 1x SDS-loading buffer (50 mM Tris-&OS+ȕ-mercaptoethanol, 2% 
SDS, 0.1% bromophenol blue, 10% glycerol) was resolved on SDS-PAGE. The proteins were 
transferred onto a nitrocellulose membrane. The cut strips of membrane corresponding with 
the appropriate protein size, e.g., E6/E6 F47R 4C/4S ~19 kDa, GFP-E6 F47R 4C/4S ~46 kDa, 
p53 ~43 kDa and GAPDH ~35 kDa, were washed and incubated with 1:1000 dilutions of E6, 
GFP, p53 or GAPDH antibodies, respectively. After washing, the membranes were then 
incubated with 1:2,000 dilutions of HRP-linked secondary antibodies. The HRP activity was 
detected by chemiluminescence. In these experiments, GAPDH served as loading control. The 
antibodies were purchased form AbCam, Cambridge, UK.  
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Figures legends 
 
Figure 1: Cu2+ complex-induced aggregation of E6 F47R 4C/4S. (A) Molecular structure of 
the Cu2+ anthracenyl-terpyridine complex. (B) Transmission electron microscopy image of E6 
F47R 4C/4S co-incubated with the Cu2+ complex. Inset in (B) shows E6 F47R 4C/4S before 
incubation. These grids were prepared at the 6 h time point. Scale bar represents 500 nm. (C) 
Analysis of E6 F47R 4C/4S aggregation by 12% SDS-PAGE. M ± molecular weight marker, 
1 ± pellet of E6 F47R 4C/4S incubated with Cu2+-perchlorate, 2 ± untreated E6 F47R 4C/4S, 3 
± pellet of E6 F47R 4C/4S incubated with Cu2+ complex and 4 ± pellet of E6 F47R 4C/4S 
incubated with 9-anthracene methanol. These samples were prepared after 6 h of co-incubation. 
The position of the asterisk indicates monomeric E6 F47R 4C/4S.  
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Figure 2: Interactions of Cu2+ complex with E6 F47R 4C/4S. (A) Fluorescence detected 
binding at 338 nm. Inset: spectral traces obtained during the titration experiment (see text). (B) 
Conformational changes in E6 F47R 4C/4S upon Cu2+ complex addition. In (A) and (B) black 
spectra corresponds to unbound E6 F47R 4C/4S and red onwards after stepwise addition of the 
Cu2+ complex (denoted by direction of arrow).  
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Figure 3: Cu2+ complex induced aggregation of E6 inside cells. (A) Cu2+ complex-treated 
HVP-infected HeLa cells showing the aggregation of E6 by phase contrast microscopy. (B) 
Fluorescence microscopy image of (A) under UV irradiation at 334 nm. (C) Half maximal 
inhibitory concentration (IC50ȝ0SORWIRUFHOOV&HOOYLDELOLW\ZDVGHWHUPLQHGXVLQJ077
assays. Error bars represent the mean of three independent experiment performed in triplicates. 
(D) Western blot analysis of E6. Lane ± 1 and 2: control HeLa cells showing the presence of 
E6 in the soluble and cell pellet fractions, respectively; lane 3 and 4: Cu2+ complex treated 
HeLa cells showing E6 in the soluble and insoluble fraction, respectively. (E) GFP-E6 F47R 
4C/4S transfected MCF-7 cells imaged using phase contract microscopy. (F) Fluorescent image 
of (E) under excitation at 488 nm. (G) Cu2+ complex treated transfected MCF-7 (tMCF-7) cells 
showing aggregation of GFP-E6 F47R 4C/4S using phase contrast microscopy. (H) Fluorescent 
image under excitation at 488 nm of (G) showing the aggregation of GFP-E6 F47R 4C/4S. 
Images in (B), (F) and (H) were pseudo-coloured using ImageJ software. (I) Western blot 
analysis of GFP-E6 F47R 4C/4S transiently expressed in MCF-7 cells. Lane ± 1 and 2: cells 
showing GFP-E6 F47R 4C/4S expression in the soluble and cell pellet fraction, respectively. 
Lane 3 and 4: Cu2+ complex treated transfected MCF-7 cells showing GFP-E6 F47R 4C/4S in 
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the soluble and insoluble fraction, respectively. In (D) and (I) GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) was used as a loading control.  
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Figure 4: Relieving of the p53 hijacking mechanism by the Cu2+ complex. (A) Western blot 
analysis of p53 in the absence and presence of the Cu2+ complex in different cells. The cells 
were treated at IC50 values for 48 h. (B) ± (G) Nuclear fragmentation of cells. (B) and (C) HeLa 
cells, (D) and (E) CaSki cells, (F) and (G) MCF-7. (B), (D) and (F) are phase contrast image 
and (C), (E) and (G) are fluorescence image of same. The cells were incubated with Cu2+ 
complex (HeLa and CaSki cells at 1 µM and MCF-7 cells at 6 µM) for 48 h. The images were 
taken by exciting the cells with UV irradiation at 334 nm. Cu2+ complex auto-fluorescence was 
utilized for imaging. (H) NMR analysis showing an overlay of 1H-15N HSQC spectra of E6 
F47R 4C/4S in the free-state (black) and bound to the Cu2+ complex (red). (I) NMR intensity 
analysis mapped onto the structure of E6 F47R 4C/4S (PDB code: 4XR8). Labelling in (H) and 
(I): residues which are assisting p53 binding are coloured blue. Residues assisting p53 binding 
and showing interaction with the Cu2+ complex (20 ± 100 % reduction of NMR intensities) are 
shown in red. Cyan residues are involved in binding to the LxxLL motif of E6AP and magenta 
residues are involved in LxxLL binding and showing reduced NMR intensities (20 ± 100 %). 
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Figure 5: NMR analysis of the E6 F47R 4C/4S/Cu2+ complex mapped onto the E6 structure 
(PDB:4XR8). (A) Colour coding follows the NMR intensity decreases (shown in (B)) upon 
Cu2+ complex addition by a color gradient: red strongly affected and white not affected 
residues. (B) Relative NMR intensity analysis of the E6 F47R 4C/4S when bound to the Cu2+ 
complex. Black filled bars are either prolines or residues which are not assigned and colored 
as white. Alternate residue labelling of the abscissa was used for clarity.  
 
 
